EQL PHARMA AB Total Liabilities
EQL PHARMA AB total liabilities. Based on the latest financial reports, EQL PHARMA AB (7JK) has total liabilities worth €583.83 Million EUR (≈ $682.56 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 7JK days of operational coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of EQL PHARMA AB (2022–2026)
Total liabilities of EQL PHARMA AB from 2022 to 2026. This chart illustrates how EQL PHARMA AB's total liabilities have evolved over time, based on quarterly financial data.
EQL PHARMA AB Competitors by Total Liabilities
The table below lists competitors of EQL PHARMA AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
iLearningEngines, Inc.
NASDAQ:AILE
|
USA | $153.76 Million |
|
DHP Korea Co. Ltd
KQ:131030
|
Korea | ₩25.12 Billion |
|
Newfield Resources Ltd
AU:NWF
|
Australia | AU$15.64 Million |
|
Inversa Prime SOCIMI S.A.
MC:YIPS
|
Spain | €37.05 Million |
|
American Lithium Corp
V:LI
|
Canada | CA$1.74 Million |
|
Garuda Indonesia Persero Tbk
JK:GIAA
|
Indonesia | Rp138.13 Trillion |
|
Tomei Consolidated Bhd
KLSE:7230
|
Malaysia | RM498.33 Million |
|
Herige SA
PA:ALHRG
|
France | €191.51 Million |
Liability Composition Analysis (2022–2026)
This chart breaks down EQL PHARMA AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see EQL PHARMA AB asset portfolio.
Liquidity & Leverage Metrics
EQL PHARMA AB Total Liabilities Ratios Explained
EQL PHARMA AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how EQL PHARMA AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for EQL PHARMA AB (2022–2026)
The table below shows the annual total liabilities of EQL PHARMA AB from 2022 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | €583.83 Million ≈ $682.56 Million |
-0.67% |
| 2025-03-31 | €587.79 Million ≈ $687.19 Million |
+199.84% |
| 2024-03-31 | €196.03 Million ≈ $229.18 Million |
+49.71% |
| 2023-03-31 | €130.94 Million ≈ $153.09 Million |
+14.60% |
| 2022-03-31 | €114.26 Million ≈ $133.58 Million |
-- |
About EQL PHARMA AB
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.